Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device
V-Go Life™ enhanced by dLife's proprietary self-management support tools
Collaboration is first announced by new dLife Healthcare Solutions Group
WESTPORT, Conn., May 22, 2012 /PRNewswire/ -- Valeritas, the maker of V-Go™ Disposable Insulin Delivery Device, a new, simple disposable device for the delivery of insulin designed especially for adults with type 2 diabetes, has selected dLife to support its state-of-the-art patient engagement program. dLife, the number-one resource and community network for people living with diabetes, and Valeritas have co-developed V-Go Life, a comprehensive diabetes lifestyle management and support program designed to increase engagement of V-Go users. This collaboration is the first of its kind from dLife's recently launched Healthcare Solutions Group, an extension of the dLife media brand that works specifically with health plans, providers, and pharmaceutical and device manufacturers to provide them diabetes engagement, behavior change, and self-management programs.
"The V-Go Life program provides comprehensive support that also addresses the issue of compliance among people living with diabetes," said Kristine Peterson, CEO of Valeritas. "By extending our solution beyond the V-Go device, we can offer people with type 2 diabetes assistance and resources throughout their entire insulin treatment regimen. Our collaboration with dLife is part of Valeritas' strong commitment to improving the lives of people with diabetes."
In this partnership, dLife's Engagement Platform is leveraged to provide users customized content and tools. Resources provided on the website include articles, videos, recipes, polls, quizzes, diet and exercise tips, expert advice, questions of the week, and more that align with and support their personal diabetes management programs, and help support the use and adoption of V-Go. V-Go Life users will be engaged in a 360-degree disease management program that contains a curriculum aimed at helping them adopt and keep engaged with the V-Go product. This will allow them to stay informed and actively engaged in their progress with their personal diabetes self-management.
"We are excited to be working with Valeritas and with the V-Go, a simple product that helps with blood sugar control for adult patients with type 2 diabetes," said Adam Kaufman, PhD, General Manager of dLife Healthcare Solutions. "The V-Go is a device that clearly fits into peoples' diabetes lifestyles and aims to significantly improve self-care; and the V-Go Life solution, built on dLife content and technology, furthers Valeritas' commitment to support the entire diabetes self-management experience."
The V-Go device makes insulin delivery convenient by delivering a continuous preset basal rate of insulin, as well as on-demand bolus dosing at mealtimes, for one 24-hour period. By eliminating the complicated regimen of injecting throughout the day and minimizing interruptions with daily activities, this method facilitates patient compliance with their therapy and may ultimately lead to improved glucose control.
Kaufman continued, "The V-Go Life program is customized to the unique demographics and experiences of V-Go patients by drawing upon the diabetes expertise and support that people with diabetes need — something dLife has been offering to diabetes consumers for many years."
V-Go Life will be available at no cost only to patients currently using the V-Go device. Patients on the V-Go device wishing to enroll in the V-Go Life program should call the 24/7 toll-free Valeritas customer care line at 1-866-881-1209.
For more information about dLife Healthcare Solutions' programs, contact Adam Kaufman at email@example.com or 203-221-3442.
About Valeritas, Inc.
Valeritas is a medical technology company committed to the development and commercialization of innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. The Valeritas medical technologies portfolio is headlined by the h-Patch™ technology. The V-Go Disposable Insulin Delivery Device, designed for the simple delivery of basal-bolus insulin therapy via a preset basal rate and on-demand bolus dosing at mealtimes, is the first use of the h-Patch™ technology.
Headquartered in Bridgewater, NJ, Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, MA. For more information on Valeritas and the V-Go™ Disposable Insulin Delivery Device, please visit www.valeritas.com and www.go-vgo.com.
About dLife – It's YOUR Diabetes Life!
dLife is the number-one community network and resource for millions of people with diabetes, their caregivers and healthcare providers. dLife engages this growing population in positive and proactive self-care across a variety of media channels. Its award-winning outlets include dLife.com, the leading online diabetes destination, attracting more than one million unique visitors a month, and featuring the widest and deepest variety of original content and resources anywhere; dLifeTV, the only national TV series dedicated to people with diabetes, with over half a million viewers, airing every Sunday on CNBC (7 p.m. ET); popular mobile applications; as well as consumer and professional programs driving proactive diabetes self-management. dLife has been recognized with numerous media and editorial awards.
dLife Healthcare Solutions applies evidence-based content and technology solutions built specifically for health plans and healthcare providers who want to engage their diabetes populations as consumers of their own healthcare and owners of their own condition. dLife has demonstrated positive and direct impact on health outcomes via a recently completed randomized trial performed by the Geisinger Healthcare System.
dLife Media Contact:
203.504.8230 ext. 107
Valeritas Media Contact:
SOURCE dLife Healthcare Solutions